SillaJen

company

About

Sillajen is a global oncolytic immunotherapeutic company.

  • 101 - 250

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$12M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status
Active

SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul South Korea and Financial District, San Francisco. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE™ platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer.

2003. Jennerex, Inc. (San Francisco, USA) was established.

2014. SillaJen acquires Jennerex, Inc.

2015. In April 2015. SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.

2015. In October 2015, SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products."

2016. In January 2016, SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer. In December 2016. SillaJen is listed on KOSDAQ market in South Korea.

2017. In may 2017, Sillajen signs collaborative agreement with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.

In July 2017, SillaJen received approval from the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer.

In Aug 2017, Sillajen signs collaborative agreement with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$12M
SillaJen has raised a total of $12M in funding over 2 rounds. Their latest funding was raised on Mar 21, 2016 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 21, 2016 Series Unknown $12M 1 Medivate Partners Detail

Investors

Number of Lead Investors
Number of Investors
1
1
SillaJen is funded by 1 investors. Medivate Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Medivate Partners Yes Series Unknown